CA2238257A1 - Endocytose d'un recepteur de facteur autocrine de mobilite (amf-r) et utilisations dans le traitement des cancers - Google Patents

Endocytose d'un recepteur de facteur autocrine de mobilite (amf-r) et utilisations dans le traitement des cancers Download PDF

Info

Publication number
CA2238257A1
CA2238257A1 CA002238257A CA2238257A CA2238257A1 CA 2238257 A1 CA2238257 A1 CA 2238257A1 CA 002238257 A CA002238257 A CA 002238257A CA 2238257 A CA2238257 A CA 2238257A CA 2238257 A1 CA2238257 A1 CA 2238257A1
Authority
CA
Canada
Prior art keywords
amf
cells
bamf
tubules
labeling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002238257A
Other languages
English (en)
Inventor
Ivan R. Nabi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Original Assignee
Universite de Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Montreal filed Critical Universite de Montreal
Priority to CA002238257A priority Critical patent/CA2238257A1/fr
Priority to CA002333021A priority patent/CA2333021A1/fr
Priority to AU38066/99A priority patent/AU3806699A/en
Priority to PCT/CA1999/000438 priority patent/WO1999061060A1/fr
Publication of CA2238257A1 publication Critical patent/CA2238257A1/fr
Priority to US10/366,319 priority patent/US20030223978A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002238257A 1998-05-22 1998-05-22 Endocytose d'un recepteur de facteur autocrine de mobilite (amf-r) et utilisations dans le traitement des cancers Abandoned CA2238257A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002238257A CA2238257A1 (fr) 1998-05-22 1998-05-22 Endocytose d'un recepteur de facteur autocrine de mobilite (amf-r) et utilisations dans le traitement des cancers
CA002333021A CA2333021A1 (fr) 1998-05-22 1999-05-13 Conjugues de ligand d'amf et d'une molecule cytotoxique pouvant etre utilises dans la therapie du cancer
AU38066/99A AU3806699A (en) 1998-05-22 1999-05-13 Conjugates of an amf ligand and a cytotoxic molecule for use in cancer therapy
PCT/CA1999/000438 WO1999061060A1 (fr) 1998-05-22 1999-05-13 Conjugues de ligand d'amf et d'une molecule cytotoxique pouvant etre utilises dans la therapie du cancer
US10/366,319 US20030223978A1 (en) 1998-05-22 2003-02-14 Conjugates of an AMF ligand and a cytotoxic molecule for use in cancer therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002238257A CA2238257A1 (fr) 1998-05-22 1998-05-22 Endocytose d'un recepteur de facteur autocrine de mobilite (amf-r) et utilisations dans le traitement des cancers

Publications (1)

Publication Number Publication Date
CA2238257A1 true CA2238257A1 (fr) 1999-11-22

Family

ID=4162458

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002238257A Abandoned CA2238257A1 (fr) 1998-05-22 1998-05-22 Endocytose d'un recepteur de facteur autocrine de mobilite (amf-r) et utilisations dans le traitement des cancers
CA002333021A Abandoned CA2333021A1 (fr) 1998-05-22 1999-05-13 Conjugues de ligand d'amf et d'une molecule cytotoxique pouvant etre utilises dans la therapie du cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002333021A Abandoned CA2333021A1 (fr) 1998-05-22 1999-05-13 Conjugues de ligand d'amf et d'une molecule cytotoxique pouvant etre utilises dans la therapie du cancer

Country Status (3)

Country Link
AU (1) AU3806699A (fr)
CA (2) CA2238257A1 (fr)
WO (1) WO1999061060A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074897A2 (fr) * 2000-04-03 2001-10-11 Curagen Corporation Proteines et acides nucleiques codant pour lesdites proteines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362278A4 (fr) * 1987-06-05 1990-05-14 Us Health Facteurs de motilite de l'autocrine dans le diagnostic et le traitement du cancer.
US5728383A (en) * 1987-10-05 1998-03-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment of tumors of the central nervous system with immunotoxins
US5382521A (en) * 1992-07-14 1995-01-17 Michigan Cancer Foundation Method of determining metastatic potential of bladder tumor cells
AU4412297A (en) * 1996-09-10 1998-04-02 Burnham Institute, The Tumor homing molecules, conjugates derived therefrom, and methods of using sa me
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser

Also Published As

Publication number Publication date
CA2333021A1 (fr) 1999-12-02
AU3806699A (en) 1999-12-13
WO1999061060A1 (fr) 1999-12-02

Similar Documents

Publication Publication Date Title
Vendeville et al. HIV-1 Tat enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responses
Rothberg et al. Caveolin, a protein component of caveolae membrane coats
Oroudjev et al. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability
Sato-Yoshitake et al. Microtubule-associated protein 1B: molecular structure, localization, and phosphorylation-dependent expression in developing neurons
DE69333574T2 (de) Gegen c-erb b-2 (her-2/neu) vewandte oberflächenantigene gerichtete immuntoxine
DE69635968T2 (de) Therapeutischer Inhibitor von glatten Muskelzellen
Shiomura et al. The molecular structure of microtubule-associated protein 1A (MAP1A) in vivo and in vitro. An immunoelectron microscopy and quick-freeze, deep-etch study
Lamb et al. Essential functions of ezrin in maintenance of cell shape and lamellipodial extension in normal and transformed fibroblasts
Yao et al. Caveolin-1 interacts directly with dynamin-2
Chen et al. Application of a proapoptotic peptide to intratumorally spreading cancer therapy
US20140004042A1 (en) Targeted delivery to human diseases and disorders
Stearns et al. Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells.
HU217220B (hu) Eljárás új sejtaktívitást szabályozó szer előállítására
JP4912556B2 (ja) 細胞質内及び／又は細胞核内への対象物質の侵入を促進するペプチド
Khine et al. CD77‐dependent retrograde transport of CD19 to the nuclear membrane: functional relationship between CD77 and CD19 during germinal center B‐cell apoptosis
JP2002541255A (ja) Ｈｅｒ族チロシンキナーゼの分解および／または阻害方法および組成物
Fahrer et al. C2-streptavidin mediates the delivery of biotin-conjugated tumor suppressor protein p53 into tumor cells
KR20180107005A (ko) Muc1에 특이적으로 결합하는 항체 및 그의 용도
US8003595B2 (en) Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
Mahmud et al. Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor
US20070248592A1 (en) Agent for inhibiting proliferation of neural stem cells
CA2238257A1 (fr) Endocytose d'un recepteur de facteur autocrine de mobilite (amf-r) et utilisations dans le traitement des cancers
US20030223978A1 (en) Conjugates of an AMF ligand and a cytotoxic molecule for use in cancer therapy
Fahrer et al. Internalization of biotinylated compounds into cancer cells is promoted by a molecular Trojan horse based upon core streptavidin and clostridial C2 toxin
Sonawane et al. Novel molecular multilevel targeted antitumor agents

Legal Events

Date Code Title Description
FZDE Dead